Skip to main content

Table 2 Response to FTM treatment according to time of TMZ failure for the entire population

From: A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy

Variable

B0

B1

B2

B3

All

Number of pts

20

50

45

48

163

Response to FTM % (N)

 CR

0

2 (1)

2.2 (1)

2.1 (1)

1.8 (3)

 PR

15 (3)

10 (5)

15.6 (7)

16.7 (8)

14.1 (23)

 SD

30 (6)

24 (12)

24.4 (11)

47.9 (23)

31.9 (52)

 DP

55 (11)

64 (32)

57.8 (26)

33.3 (16)

52.1 (85)

Disease Control % (N)

 Yes

45 (9)

36 (18)

42.2(19)

66.7 (32)

47.8 (78)

PFS-6 m % (N)

 Yes

25 (5)

28 (14)

31.1 (14)

43.8 (21)

33.1 (54)

OS-1y % (N)

     

 Yes

25 (5)

24 (12)

28.9 (13)

31.3 (15)

27.6 (45)

Time to DP after FTM

 Days median (range)

111

(83 - 182)

91

(43 - 156)

104

(58 - 190)

139

(62 - 252)

104

(58 - 193)

  1. CR: complete response; PR: partial response; SD: stable disease; DP: disease progression; PSF-6 m: progression free survival at 6 months; OS-1y: overall survival at 1 year; FTM: fotemustine. B0: patients failing after radiotherapy completion and before starting adjuvant TMZ; B1: patients failing during the first 6 months of adjuvant TMZ; B2: patients who failed after more than 6 months of therapy; B3: patients who experienced tumor recurrence after a treatment-free interval.